Genome-wide meta-analysis identifies nine loci associated with higher risk of hepatocellular carcinoma development
- PMID: 40823170
- PMCID: PMC12355075
- DOI: 10.1016/j.jhepr.2025.101485
Genome-wide meta-analysis identifies nine loci associated with higher risk of hepatocellular carcinoma development
Abstract
Background & aims: The genetic underpinnings of hepatocellular carcinoma (HCC) remain largely unknown. Thus, we aimed to identify new genetic risk loci for HCC.
Methods: We performed a genome-wide association study (GWAS) meta-analysis of 11 cohorts with validation in two independent cohorts. The identified variants were tested for effects on other hepatobiliary endpoints, and on incident HCC stratified by underlying risk factors. Mendelian randomization was used to assess the causal effects of a range of traits on the risk of HCC.
Results: In meta-analyses totaling 6,540 cases and 2,096,759 controls, we identified 10 associations with HCC, of which five (in KLF15, HSD17B13, APOE, HFE, and MTARC1) have not previously been implicated in HCC at genome-wide statistical significance. Known associations in PNPLA3, TM6SF2, TERT, IFNL4, and HLA-DP1 were confirmed. All associations except KLF15 were validated in independent cohorts totaling 7,630 cases and 733,689 controls. The largest per-allele effect was seen for TM6SF2 (beta = 0.61) followed by PNPLA3 (0.55), HFE (0.45), IFNL4 (0.31), APOE (0.27), HSD17B13, HLA-DP1, and TERT (all 0.21), and MTARC1 (0.17). The identified variants had comparable effects on incident HCC in individuals with prevalent obesity, a high alcohol intake, diabetes, or cirrhosis. Mendelian randomization analyses confirmed the causal role of obesity in HCC. We found strong correlations between genetic effects on HCC and hepatic steatosis (r2 = 0.75), and HCC and cirrhosis (r2 = 0.69), whereas only three loci (APOE, HFE, and TERT) had concordant effects on HCC and biliary tract cancer.
Conclusions: We identified and validated nine genetic variants associated with an increased risk of HCC development.
Impact and implications: The genetic underpinnings of HCC remain largely unknown. In this genome-wide association meta-analysis totaling 6,540 cases with HCC and 2.1 million controls, we identified and validated nine genetic loci to associate with the risk of HCC. A deeper insight into genetic factors that affect the risk of HCC could improve our ability to predict and ultimately prevent or treat this deadly cancer.
Keywords: Biliary tract cancer; Cirrhosis; HCC; MASLD; PNPLA3.
© 2025 The Author(s).
Conflict of interest statement
The authors who are affiliated with deCODE genetics/Amgen declare competing financial interests as employees. JG has received lecture fee from Illumina. SV has served as consultant for Albireo and received research funding from Moderna Therapeutics, with no relevance to this study. SB is a board member for Proscion A/S and Intomics A/S. JBA has received consulting fees from AstraZeneca (Nordic), QED Therapeutics, and Flagship Pioneering as well as project funding from Incyte Corp and ADCendo (not related to this study). HB receives lecture fees from Bristol-Myers Squibb, Merck Sharp and Dohme. SS has served as consultant for Regeneron and received a lecture fee from Amgen. All other authors have no conflict of interest to declare. Please refer to the accompanying ICMJE disclosure forms for further details.
Figures
References
-
- Bray F., Laversanne M., Sung H., et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–263. - PubMed
-
- Vogel A., Meyer T., Sapisochin G., et al. Hepatocellular carcinoma. Lancet. 2022;400:1806–1807. - PubMed
-
- Dragani T.A. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol. 2010;52:252–257. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
